Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,432 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Recruiting Phase 1 Interventional

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Duarte, California • San Francisco, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Improving the Outcomes of Adolescents With ADHD Via a Pre-visit Question Prompt List/Video Intervention

NCT05835362
View directory record Official record
Conditions
ADHD
Interventions
Question Prompt List, Video Only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Active, not recruiting Phase 1 Interventional

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391
View directory record Official record
Conditions
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19CAR-28-zeta T cells, Ipilimumab
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Interventions
BGB-B2033, Tislelizumab, Bevacizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

NCT04464577
View directory record Official record
Conditions
Healthy Participants
Interventions
Fluconazole, Bupropion, Itraconazole, BMS-986235
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

NCT01298401
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ganitumab, capecitabine, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Orange, California • Newark, Delaware • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928
View directory record Official record
Conditions
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions
Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

NCT03382977
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
VBI-1901, Carmustine, Lomustine
Biological · Drug
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595
View directory record Official record
Conditions
Advanced or Metastatic Colorectal Cancer
Interventions
Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT07181681
View directory record Official record
Conditions
Solid Tumors, Advanced Solid Tumor
Interventions
BG-C0902
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study

NCT02381366
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Biological
Lead sponsor
Medipost, Inc.
Industry
Eligibility
3 Days to 14 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

NCT05027945
View directory record Official record
Conditions
Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions
Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY)
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study

NCT01090557
View directory record Official record
Conditions
RSV Infection, Bronchiolitis
Interventions
Collection of exhaled breath
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
1 Day to 4 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2010 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

NCT04998851
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Yuma, Arizona • Hialeah, Florida • Orange City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation for Patients With Cancers of the Blood

NCT00467961
View directory record Official record
Conditions
CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), AML (Acute Myelogenous Leukemia), Acute Lymphocytic Leukemia, MDS (Myelodysplastic Syndrome)
Interventions
Miltenyi system
Combination Product
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Not listed Phase 1 Interventional

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

NCT05003141
View directory record Official record
Conditions
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
Interventions
PSB202
Drug
Lead sponsor
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

NCT04935359
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study of XOMA 3AB

NCT01357213
View directory record Official record
Conditions
Botulism
Interventions
XOMA 3AB, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

NCT01745913
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, Rabbit ATG, Double Umbilical Cord Blood Transplantation, Haplo-Identical Cord Transplantation
Device · Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449
View directory record Official record
Conditions
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Interventions
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 21, 2026, 5:22 PM EDT